Genmab develops antibody-based therapies to treat cancer. The company discovers, develops, and commercializes proprietary antibody technologies and treatments designed to target and kill cancer cells, often in collaboration with other biotech or pharmaceutical partners. Its products work by using antibodies that recognize specific cancer cell markers, helping the immune system or the drugs attack and destroy those cells. Genmab differentiates itself through its own patented antibody platforms and its focus on strategically partnering for development and commercialization, allowing it to leverage scientific expertise and shared resources rather than relying on a single product. The company aims to turn scientific insights into approved cancer medicines that improve patient outcomes while building value through licensing deals and collaborations with researchers and drug developers around the world.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Copenhagen, Denmark
Founded
1999
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?